# Mounjaro sales double this year as obesity drug boom prevails, says maker

By Danni Hewson — 2026-08-05

Following news that sales of weight loss and diabetes jab Mounjaro have doubled over the past year, AJ Bell’s Danni Hewson has commented on manufacturer Eli Lilly’s success.

Danni Hewson, head of financial analysis at AJ Bell, said: “The fortunes of weight loss drug leaders Eli Lilly and Novo Nordisk have wildly diverged in recent years and that pattern was repeated as both companies published their quarterly earnings.

“Novo’s shares in Copenhagen slumped as companies fretted about over-reliance on obesity treatments, which account for upwards of 90 per cent of revenue, and slowing sales in the US. Though reassuring comments from CEO Mike Doustdar helped the company’s ADRs in New York to eke out modest gains.

“Eli Lilly enjoyed a more unambiguously positive response from the market. It is not as heavily reliant on the weight loss space and upped its revenue guidance for the full year.

“If the battle between these two dominant players were a couch to 5k effort, Novo would still be sunk into the sofa cushions while Eli Lilly is out running laps around the park.”

Canonical: https://experts.pressassociation.com/expert/9/views/dad4010340b7468c